Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
- Written by PR Newswire
- Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) -
- Expanding bioMUSE Natural History Study -
MELBOURNE, Australia and SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE)...
Read more: Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program